Skip to main content
Premium Trial:

Request an Annual Quote

Immunai Acquires Dropprint Genomics

NEW YORK — Immune profiling firm Immunai said on Thursday that it has acquired single-cell genomics software company Dropprint Genomics for an undisclosed amount.

New York City-based Immunai, which has offices in San Francisco and Tel Aviv, said the acquisition is providing it with technologies San Francisco-based Dropprint has developed for handling the computational demands of large-scale single-cell sequencing and for more cost-effectively processing large numbers of patients samples.

Additionally, Dropprint, a Y Combinator-backed startup, has built a database of immune cell profiles from autoimmune and cancer patients that Immunai will incorporate into its Annotated Multi-omic Immune Cell Atlas (AMICA).

Dropprint's employees, including cofounders Meena Subramaniam and Rachel Gate, are joining Immunai's machine learning and computation biology team.

The acquisition comes a month after Immunai raised $60 million in a Series A financing round. The company said it has raised $80 million in funding to date.

For a more in-depth look at Immunais acquisition of Dropprint, click here.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.